News
Five months after selling a cancer drug to Lilly for up to $2.5 billion, Scorpion has debuted a successor company led by its ...
The spinout, dubbed Antares Therapeutics, will be fueled by a $177 million series A round co-led by Omega Funds, Atlas ...
'We are in a good spot': Gilead's new chief medical officer is committed to pipeline diversification
Dietmar Berger, M.D., Ph.D., joined Gilead Sciences as chief medical of | Dietmar Berger became Gilead Sciences’ new chief ...
Cullinan Therapeutics (NASDAQ:CGEM) signed a deal with Genrix Bio for an exclusive license for velinotamig, a bispecific T ...
Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry ...
The Alzheimer's agreement – with Denmark's Muna Therapeutics – will see the ... Rgenta's in-house pipeline is headed by RGT-61159, a drug designed to inhibit the production of the cancer ...
Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback